- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07947173
Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants
Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
(1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.
(5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.
(6) Female participants must meet the following criteria:
-
Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
-
Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.
(7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
(8) Able to fully understand and voluntarily sign the informed consent form.
-
Exclusion Criteria:
-
(1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.
(2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.
(4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.
(5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.
(7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.
(8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.
(9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.
(11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.
(12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).
(13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.
(15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).
(16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low-dose JCXH-105
Participants receive low dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
위약 비교기: Low-dose placebo
Participants receive low dose of placebo |
Placebo (sodium chloride injection) as control |
|
실험적: Medium-dose JCXH-105
Participants receive medium dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
위약 비교기: Medium-dose placebo
Participants receive medium dose of placebo |
Placebo (sodium chloride injection) as control |
|
실험적: High-dose JCXH-105
Participants receive high dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
위약 비교기: High-dose placebo
Participants receive high dose of placebo |
Placebo (sodium chloride injection) as control |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serious adverse events (SAEs)
기간: From Day 1 post- administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post- administration through 360 days after the full-course vaccination
|
|
Solicited local injection site adverse events
기간: Within 14 days after each dose of investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of investigational vaccine/placebo
|
|
Solicited systemic adverse events
기간: Within 14 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of the investigational vaccine/placebo
|
|
Unsolicited AEs
기간: Within 30 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 30 days after each dose of the investigational vaccine/placebo
|
|
Laboratory parameters
기간: On the third day after each dose of the investigational vaccine/placebo
|
Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination |
On the third day after each dose of the investigational vaccine/placebo
|
|
Adverse events of special interest (AESIs)
기간: From Day 1 post administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post administration through 360 days after the full-course vaccination
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- JCXH-105-002
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .